Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) announced on Friday the availability of the US Food and Drug Administration (FDA) approved Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.

Dr. Reddy's Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection.

It available in 200 mcg/50 mL (4 mcg/ml) and 400 mcg/100 ml (4 mcg/ml) in 50 ml and 100 ml clear glass vials, respectively. The strength is based on the dexmedetomidine base. Containers are intended for single-dose only.

For the 12 months to June 2020, the Precedex in 0.9% Sodium Chloride Injection brand and generic market had US sales of approximately USD210m MAT, according to IQVIA Health.

Dexmedetomidine, sold under the trade name Precedex, is an anxiety reducing, sedative and pain medication.